786 related articles for article (PubMed ID: 14601692)
61. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
62. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia.
Diehl LF; Ketchum LH
Semin Oncol; 1998 Feb; 25(1):80-97. PubMed ID: 9482530
[TBL] [Abstract][Full Text] [Related]
63. Successful treatment with rituximab of refractory idiopathic thrombocytopenic purpura in a patient with Kabuki syndrome.
Torii Y; Yagasaki H; Tanaka H; Mizuno S; Nishio N; Muramatsu H; Hama A; Takahashi Y; Kojima S
Int J Hematol; 2009 Sep; 90(2):174-176. PubMed ID: 19662467
[TBL] [Abstract][Full Text] [Related]
64. Outcome of laparoscopic splenectomy based on hematologic indication.
Rosen M; Brody F; Walsh RM; Tarnoff M; Malm J; Ponsky J
Surg Endosc; 2002 Feb; 16(2):272-9. PubMed ID: 11967677
[TBL] [Abstract][Full Text] [Related]
65. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia.
Rossignol J; Michallet AS; Oberic L; Picard M; Garon A; Willekens C; Dulery R; Leleu X; Cazin B; Ysebaert L
Leukemia; 2011 Mar; 25(3):473-8. PubMed ID: 21127498
[TBL] [Abstract][Full Text] [Related]
66. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
Saleh MN; Gutheil J; Moore M; Bunch PW; Butler J; Kunkel L; Grillo-López AJ; LoBuglio AF
Semin Oncol; 2000 Dec; 27(6 Suppl 12):99-103. PubMed ID: 11226008
[TBL] [Abstract][Full Text] [Related]
67. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R
Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
[TBL] [Abstract][Full Text] [Related]
68. Monoclonal antibodies in the treatment of autoimmune cytopenias.
Robak T
Eur J Haematol; 2004 Feb; 72(2):79-88. PubMed ID: 14962245
[TBL] [Abstract][Full Text] [Related]
69. Combined autoimmune cytopenias.
Martino R; Muñiz-Díaz E; Arilla M; Ibáñez M; Altés A; Guanyabens C; Madoz P
Haematologica; 1995; 80(4):305-10. PubMed ID: 7590498
[TBL] [Abstract][Full Text] [Related]
70. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
[TBL] [Abstract][Full Text] [Related]
71. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
Zhu YC; Wang W; Zhou YH; Wang XM; Wang X; Wang YL; Sun GZ; Hou M
Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
[TBL] [Abstract][Full Text] [Related]
72. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
73. [Autoimmune hemolytic anemia].
Karasawa M
Nihon Rinsho; 2008 Mar; 66(3):520-3. PubMed ID: 18326320
[TBL] [Abstract][Full Text] [Related]
74. A novel immunomodulatory treatment involving mycophenolate mofetil and corticosteroids for pediatric autoimmune cytopenias.
Panigrahi A; Clark A; Myers J; Raj A
Pediatr Blood Cancer; 2017 Feb; 64(2):287-293. PubMed ID: 27615037
[TBL] [Abstract][Full Text] [Related]
75. Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab.
Bhatt V; Shune L; Lauer E; Lubin M; Devlin SM; Scaradavou A; Parameswaran R; Perales MA; Ponce DM; Mantha S; Kernan NA; Barker JN
Bone Marrow Transplant; 2016 Dec; 51(12):1579-1583. PubMed ID: 27643868
[TBL] [Abstract][Full Text] [Related]
76. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia.
Barcellini W; Zaja F; Zaninoni A; Imperiali FG; Di Bona E; Fattizzo B; Consonni D; Cortelezzi A; Zanella A
Eur J Haematol; 2013 Dec; 91(6):546-51. PubMed ID: 24033754
[TBL] [Abstract][Full Text] [Related]
77. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura.
Delgado J; Bustos JG; Jimenez-Yuste V; Hernandez-Navarro F
Haematologica; 2002 Feb; 87(2):215-6. PubMed ID: 11836172
[TBL] [Abstract][Full Text] [Related]
78. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura.
Vancine-Califani SM; De Paula EV; Ozelo MC; Orsi FL; Fabri DR; Annichino-Bizzacchi JM
Platelets; 2008 Nov; 19(7):489-95. PubMed ID: 18979360
[TBL] [Abstract][Full Text] [Related]
79. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
80. [Mixed-type autoimmune hemolytic anemia after splenectomy for idiopathic thrombocytopenic purpura].
Toyota S; Nakamura N; Dan K
Rinsho Ketsueki; 2001 Jan; 42(1):51-3. PubMed ID: 11235135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
